Can Botox really help treat vaginismus - and what do the success rates actually look like for someone considering it?
Dr. Corey Babb is a board-certified gynaecologist, ISSWSH fellow, and one of only four providers worldwide trained in the Pacik Multimodal Botox Protocol for vaginismus. He is the founder of Haven Center in Tulsa, Oklahoma, and the co-author of a five-point vaginismus grading scale that expands the clinical framework for assessment. His Instagram is @dr.coreybabb and his website is havencenter.com. In this episode, Dr. Babb explains how Botox works physiologically for vaginismus, breaks down the grading system, shares real success rates from his practice, and covers what the treatment process and recovery actually look like.
Understanding vaginismus: the five-point grading scale
The standard Lamont scale for grading vaginismus runs from 1 to 4, describing progressively severe levels of muscle spasm and avoidance. Dr. Babb co-authored an expansion of this scale that adds a fifth grade - characterised by what he describes as "almost pure dissociation" - in which the psychological protective response is so dominant that standard physical examination and treatment become difficult to carry out. This additional grade matters clinically because it points toward a treatment approach that must address the psychological dimension alongside the physical.
Understanding where a patient sits on this scale informs everything about how treatment is sequenced: how much preparatory psychological work is needed, what the Botox protocol should include, and what the realistic timeline for progress looks like. For people who have found that standard approaches haven't worked, knowing that there is a clinical framework that accounts for the most severe presentations - and a treatment pathway designed for them - is significant.
"I now know she had vaginismus. I didn't know at the time even what that was."
How Botox breaks the pain-fear-spasm cycle
The physiological mechanism of Botox in vaginismus treatment is direct: the toxin temporarily blocks the nerve signals that cause the targeted pelvic floor muscles to contract, which interrupts the cycle of spasm, pain, and fear that maintains vaginismus. With the involuntary contraction removed, the window of opportunity opens for the graded dilator work and desensitisation that wouldn't be possible with the spasm response intact.
Dr. Babb's clinic reports a success rate of approximately 95% of patients achieving pain-free penetration within three months - a figure that significantly outperforms standard physiotherapy-only protocols for severe presentations. He explains why this success rate is achievable, what the post-procedure protocol looks like, and why relapse rates are low in patients who complete the full treatment programme. He is also clear about who is and isn't a good candidate for Botox, and what the alternative pathways are.
Botox for vulvodynia: a different application
Botox is better known as a vaginismus treatment, but Dr. Babb also uses it for a subset of vulvodynia patients - specifically those with hypertonic pelvic floor dysfunction where the muscular tension component is driving vulvar pain. The application is different, the injection sites are different, and the criteria for candidacy are different, but the underlying principle is the same: interrupting the muscle-driven component of pain to create space for broader treatment.
He discusses how he assesses whether a vulvodynia patient is likely to respond to Botox, what the overlap with vaginismus presentations looks like, and what other treatment approaches are running in parallel with the Botox work. Trauma-informed care and patient agency throughout the treatment process are central to his practice and are discussed specifically in the episode.
The future of vulvovaginal pain treatment: mast cell activation and what's coming
Dr. Babb is engaged with the research frontier of vulvovaginal pain treatment - in particular, the emerging understanding of mast cell activation's role in maintaining vestibular inflammation and nerve sensitisation. He discusses what the current evidence shows about mast cell involvement, what treatment approaches targeting this mechanism look like, and where clinical trials are currently focused.
For patients who have completed standard treatment pathways without adequate relief, understanding the next wave of research - and the clinical trials that may be available - is valuable information. Dr. Babb's position at the intersection of clinical practice and research makes him a reliable guide to what is currently being investigated and what the next few years of treatment development may look like.
